SCHEMBL4911752

SCHEMBL4911752

O=C1CNC(=O)N1CC=Cc1ccc(-c2ccc(F)cc2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GRM2 Q14416 1/20 0.38
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36
PTPN11 Q06124 1/20 0.36
HSD11B1 P28845 1/20 0.33
MLNR O43193 4/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
CYP2D6 P10635 3/20 0.32
SIGMAR1 Q99720 2/20 0.32
KCNH2 Q12809 3/20 0.32
HTR2A P28223 2/20 0.32
ADRA2A P08913 2/20 0.32
ADRA2B P18089 2/20 0.32
HTR4 Q13639 1/20 0.32
AURKA O14965 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911748 1.00 NPC1 (0.39) NPC1RXFP1GRM2CYP11B1CYP11B2
Trifluoroacetic Acid SCHEMBL3872911 0.92 NPC1 (0.39) NPC1RXFP1GRM2CYP11B1CYP11B2
Trifluoroacetic Acid SCHEMBL3872908 0.92 NPC1 (0.39) NPC1RXFP1GRM2CYP11B1CYP11B2
SCHEMBL4918921 0.85 NPC1 (0.40) NPC1RXFP1CYP11B1CYP11B2PTPN1
SCHEMBL4918925 0.85 NPC1 (0.40) NPC1RXFP1CYP11B1CYP11B2PTPN1
SCHEMBL3874171 0.83 MEN1 (0.38) NPC1RXFP1GRM2CYP11B1CYP11B2
SCHEMBL3874170 0.83 MEN1 (0.38) NPC1RXFP1GRM2CYP11B1CYP11B2
SCHEMBL4919703 0.81 GRM2 (0.39) GRM2GSK3AGSK3BGRIN2B
SCHEMBL4919710 0.81 GRM2 (0.39) GRM2GSK3AGSK3BGRIN2B
SCHEMBL4909360 0.81 GRM5 (0.42) NPC1GRM2MLNRCYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167342-A1 Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals SANOFI-AVENTIS (FR) 2008-07-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167342-A1 Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals TBXAS1, PTGIS, NOS2 NPC1 2910/4885RXFP1 708/4885GRM2 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.